Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced inducement equity awards on November 3, 2025. On October 31, 2025, the company granted inducement stock options to purchase 170,750 shares to seven new non-executive employees under the 2024 Inducement Equity Incentive Plan.

Each option has an exercise price of $18.28 (equal to the closing price on the grant date). Vesting is 25% after one year, then 1/48th monthly thereafter, subject to continued service. Awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4).

BOULDER, Colo., Nov. 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on October 31, 2025, Edgewise granted inducement stock options to purchase a total of 170,750 shares of Edgewise's common stock to 7 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan"). 

Each inducement stock option has an exercise price of $18.28 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302601499.html

SOURCE Edgewise Therapeutics

FAQ

What did Edgewise (EWTX) grant on October 31, 2025?

Edgewise granted inducement stock options to purchase 170,750 shares to seven new non-executive employees.

What is the exercise price of the EWTX inducement options granted Oct 31, 2025?

Each inducement option has an exercise price of $18.28 per share, equal to the closing price on the grant date.

How do the EWTX inducement options vest for new hires?

Vesting is 25% after one year from each employee's start date, then 1/48th monthly thereafter, subject to continued service.

Why did Edgewise use inducement grants under Nasdaq Listing Rule 5635(c)(4)?

The awards were granted as inducements material to these employees to enter employment, consistent with Nasdaq Listing Rule 5635(c)(4).

Do the Oct 31, 2025 EWTX inducement grants immediately dilute existing shareholders?

The grants are options to purchase shares; dilution would occur only if and when options are exercised, subject to their terms.

Where can investors find more details about Edgewise's inducement awards (EWTX)?

Details are disclosed in the company's announcement and related inducement award agreements under the 2024 Inducement Equity Incentive Plan.